A carregar...
(177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
INTRODUCTION: (177)Lutetium-[DOTA°,Tyr(3)]octreotate ((177)Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. The therapy appr...
Na minha lista:
| Publicado no: | Expert Rev Gastroenterol Hepatol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7227421/ https://ncbi.nlm.nih.gov/pubmed/31652074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17474124.2019.1685381 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|